Here is the design of a clinical trial:

Official Title: Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder: A Randomized Controlled Trial

Included conditions:
- Opioid Use Disorder

Study Armgroups:
- {'label': 'Rapid Micro-Induction', 'type': 'EXPERIMENTAL', 'description': 'On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 8mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) for withdrawal symptoms and/or craving and/or pain - maximum daily dose of 32mg. Afterwards, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 32mg. On Days 1 and 2, participants will concurrently receive 1-48mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) Q1 to 3H PRN for withdrawal symptoms and/or craving and/or pain, titrated to effect (start at lower end of dosing range). Hydromorphone will be discontinued on Days 3 onwards.', 'interventionNames': ['Drug: Buprenorphine/naloxone', 'Drug: Hydromorphone']}
- {'label': 'Standard Induction', 'type': 'ACTIVE_COMPARATOR', 'description': 'Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2 or 4mg bup/nx SL. If their COWS score increases, bup/nx will be held. If their COWS score remains the same or decreases, additional dosing can be done in increments of 2mg bup/nx SL every 2 hours (Q2H) as needed (PRN). On Day 2, dosing will be consolidated to once daily dosing. The maximum total daily dose for Day 1 and 2 is 32mg.', 'interventionNames': ['Drug: Buprenorphine/naloxone']}

Interventions:
- {'type': 'DRUG', 'name': 'Buprenorphine/naloxone', 'description': 'Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.', 'armGroupLabels': ['Rapid Micro-Induction', 'Standard Induction'], 'otherNames': ['Suboxone']}
- {'type': 'DRUG', 'name': 'Hydromorphone', 'description': 'Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.', 'armGroupLabels': ['Rapid Micro-Induction'], 'otherNames': ['Dihydromorphinone, Dilaudid']}

Primary Outcomes:
- {'measure': 'Successful induction of bup/nx with low levels of withdrawal', 'description': 'This is defined as the following: participants who remain in treatment until they have received a total daily dose of ≥ 8mg of bup/nx (successful induction), and score ≤ 12 on the COWS (low levels of withdrawal) from baseline to when they reach that dose.', 'timeFrame': 'Baseline to Day 1 (Standard Induction Arm) or Day 2 (Rapid Micro-Induction Arm)'}

Please estimate the sample size based on the assumption: 
Type I error of 0.05, Type II error of 0.1, and an attrition rate of 10%.
Sample size and power calculation
      The sample size calculation for the binary primary outcome is based on testing for superiority in a parallel group clinical trial. As only case reports have been published on rapid micro-induction, we expect a success rate of 95% in the experimental arm based on the opinion of two addiction psychiatry experts familiar with the method. We expect a success rate of 10% in the control arm, as most participants in the arm are anticipated to experience moderate to higher levels of withdrawal, which is defined as having a COWS score of â¥â13. A difference of such a magnitude, 85%, is deemed clinically meaningful. Using G*Power 3.1 software, the minimum required sample size to power a Fisherâs exact test to detect this difference between the two arms with a type I error of 0.05 and a type II error of 0.1 will be 12 (6 in each arm). Adjusting for an attrition rate of 10% (participants with incomplete COWS data, participants who have discontinued the treatment they were randomized, and participants who have discontinued both treatment and data collection procedures), the required sample size is 14. We aim for a sample size of 50 (25 each arm), as a larger sample size is not feasible due to cost and constraints.